DEPENDABLE SOLUTIONS
FOR COMPLEX OCCLUSIONS

Clinical Evidence RESTOR-1 Study1

AngioSafe’s Atheroplasty™ platform is backed by rigorous clinical evaluation. Designed to enable safe, efficient, wire-free crossing and recanalization of complex occlusions.

RESTOR-1 Pivotal Trial:

A prospective, multi center, pivotal study, conducted at 14 sites in the United States with 70 per protocol patients enrolled, treated, and core lab adjudicated.

Objective:

To demonstrate the safety and effectiveness of the Santreva-ATK System to facilitate crossing of CTOs in the peripheral vasculature.

Key Inclusion Criteria:

  • Rutherford Classification Criteria 2-5
  • Femoropopliteal arteries
  • 99-100% stenosed
  • Max 300mm long, regardless of calcium severity

Primary Endpoint:

Clinical success of Santreva-ATK to facilitate placement of guidewire into the distal true lumen of the femoropopliteal artery CTO, in the absence of device-related major adverse events (MAE) through discharge or 24 hours post-procedure, whichever is sooner.

AngioSafe’s Santreva-ATK Endovascular Revascularization Catheter delivers compelling
results where it matters most.

90 %
overall success
> 55 %
mean lumen gain2
0
device-related MAEs
0
embolization
0
major perforation
0
flow-limiting dissections
or bailout stent
24
mean crossing

time (min)
9
median crossing

time (min)
84
mean lesion

length (mm)

What’s driving adoption is the strength and consistency of the clinical data. The outcomes we’re seeing translate directly into real-world practice, giving physicians the confidence to move from early experience to routine commercial use.

Subhash Banerjee, MD, FACC, FSCAI

National Principal Investigator, AngioSafe Peripheral Program Chief of Cardiovascular Research and Innovation for Baylor Scott & White Heart and Vascular Hospital, Texas, USA

Built to perform where patient and
lesion complexity converge

80 %
of IVUS evaluated crossings
were completely intraluminal
~ 85 %
single access only

Breakthrough performance that goes beyond crossing

>55% lumen gain and a ~6.5mm2 average cross sectional area following Santreva-ATK crossing only2

Santreva-ATK performs both crossing and lumen revascularization.

Bar chart showing Santreva-ATK's lumen gain (54-60%) across various calcification severities, confirming vessel opening.

Traditional revascularization procedures rely on multiple devices to cross, then open the vessel. Our technology merges those steps — delivering a more efficient, streamlined experience with the potential to reduce complications, reduce procedure times, and improve outcomes.

Significant Improvement in Rutherford Classification and Pain Scores

Mean Rutherford score decreased from 3.41 to 1.20 and mean pain numeric rating decreased from 5.12 to 1.87 at 30 days.

From Proximal Cap to True Lumen
Introducing the Santreva-ATK Endovascular Revascularization Catheter

Santreva-ATK is an all-in-one, large-profile, manually controlled, and guidewire-free endovascular revascularization solution, with full force range and control to tackle the wide range of plaque morphologies, designed to limit damage to the vessel wall.

1Banerjee, S. et al.  Am J Cardiol. 2026 Mar 15:263:33-42